Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

AR positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2	enzalutamide Sensitive: C2 – Inclusion Criteria enzalutamide Sensitive : C2
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Estrogen Receptor Positive Breast Cancer	AR positive	Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2	enobosarm Sensitive: C2 – Inclusion Criteria enobosarm Sensitive : C2
AR positive	Breast Cancer	AR positive	Breast Cancer	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2	GT0918 Sensitive: C2 – Inclusion Criteria GT0918 Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	abiraterone acetate Sensitive: C3 – Early Trials abiraterone acetate Sensitive : C3	abiraterone acetate Sensitive: C3 – Early Trials abiraterone acetate Sensitive : C3
AR positive	Ovarian Cancer	AR positive	Ovarian Cancer	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3	enzalutamide Sensitive: C3 – Early Trials enzalutamide Sensitive : C3